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MethylphenidateMethylphenidate (MPH) is the preferred treatment used for attention-deﬁcit/hyperactivity disorder (ADHD).
Recently, misuse for MPH due to its apparent cognitive enhancer properties has been reported. Adenosine is a
neuromodulator known to exert inﬂuence on the dopaminergic neurotransmission, which is the main
pharmacological target of MPH. We have reported that an overdosage of MPH up-regulates adenosine A1
receptors in the frontal cortex, but this receptorwas not involved in its anxiolytic effects. In this study, the role of
adenosine A1 receptor was investigated on MPH-induced effects on aversive and recognition memory in adult
mice. Adult mice received acute and chronic (15 days) administration of methylphenidate (5 mg/kg, i.p.), or an
acute overdosage (50 mg/kg, i.p) in order to model misuse. Memory was assessed in the inhibitory avoidance
and object recognition task. Acute administration 5 mg/kg improved whereas 50 mg/kg disrupted recognition
memory and decreased performance in the inhibitory avoidance task. Chronic administration did not cause any
effect on memory, but decreased adenosine A1 receptors immunocontent in the frontal cortex. The selective
adenosine A1 receptor antagonist, (DPCPX 1 mg/kg, i.p.), prevented methylphenidate-triggered recognition
memory impairment. Our ﬁndings showed that recognition memory rather than aversive memory was
differently affected by acute administration at both doses. Memory recognition was fully impaired by the
overdosage, suggesting that misuse can be harmful for cognitive functions. The adenosinergic system via A1
receptors may play a role in the methylphenidate actions probably by interfering with dopamine-enhancing
properties of this drug.ty disorder; DMSO, dimethyl
MPH, Methylphenidate; SHR,
noamine transporter 2.
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Methylphenidate (MPH) has a long history of being an effective
medication for attention-deﬁcit/hyperactivity disorder (ADHD). The
increase in stimulant prescriptions has resulted in a corresponding
intensiﬁcation of illicit use, particularly among college students
(Advokat et al., 2008; Rabiner et al., 2009; Teter et al., 2006).
The nonmedical use of MPH has increased in the American college
setting because most students report using stimulant medications in
an attempt to enhance academic performance, speciﬁcally to increase
concentration, organization, and the ability to stay up longer and
study (Dupont et al., 2008; Godfrey, 2009). Besides, stimulants arealso consumed for recreactional reasons and they are often in
combination with alcohol. Although stimulant therapy in childhood
does not increase the risk for subsequent drug abuse in youth with
ADHD (Barkley et al., 2003; Wilens et al., 2003), the recent escalation
in use among adolescents and young adults has raised concern about
the prevalence of stimulant diversion andmisuse, and initiated debate
about the ethical implications of using drugs to improve academic
performance.
Recently, a systematic review was focused on MPH administration
on cognitive functions in healthy humans, and the available data and
the analysis performed do not allow for a conclusion to be drawn
about its cognitive enhancer property (Repantis et al., 2010). In
rodents, recent developmental studies demonstrating MPH effects on
object recognition memory (Britton et al., 2007; Heyser et al., 2004;
LeBlanc-Duchin and Taukulis, 2007) and memory for learned
contextual fear associations (Britton et al., 2007) suggest that
hippocampal-sensitive tasks are affected by MPH exposure during
adolescence.
Similar to other psychostimulants, the dopaminergic system is one
of the main targets of pharmacological action for MPH (Gatley et al.,
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take place (Pascoli et al., 2005; Prieto-Gómez et al., 2005). Adenosine
is a neuromodulator in the central nervous system (CNS), which via
mainly adenosine A1 and A2A metabotropic receptors control synaptic
transmission of neurotransmitters such as dopamine and glutamate
(Cunha, 2001).
Adenosine A1 receptors are expressed throughout the brain while
adenosine A2A are more restricted to the basal ganglia. The existence
of selective heteromerization of A2A and D2 receptors and A1 and D1
receptors was ﬁrstly demonstrated in transfected cells followed
by biochemical analysis (Agnati et al., 2003; Canals et al., 2003;
Ginés et al., 2000), therefore demonstrating the existence of A2A–D2
and A1–D1 receptor heteromers in the brain (Ferré et al., 1997; Franco
et al., 2007). The A1–D1 heteromeric receptor complex may therefore
give the molecular basis for the well-documented antagonistic A1–D1
receptor/receptor interactions found in the neuronal networks of the
brain (Ferré et al., 1997; Fuxe et al., 1998). The understanding of these
receptor/receptor interactions has been useful for the development of
novel treatments for some neuropathologies that include ADHD,
Parkinson's disease, dyskinesias, schizophrenia, and drug addiction
(for reviews see Ferré et al., 2008; Fuxe et al., 2007; Maggio et al.,
2009).
The participation of adenosinergic system in the ADHD has been
suggested in studies with spontaneously hypertensive rats (SHR) as
an experimental model of ADHD. Caffeine (a non-selective adenosine
receptors antagonist) and selective adenosine receptors antagonists
reversed the memory impairment in this strain (Pires et al., 2009;
Prediger et al., 2005).
The involvement of adenosine receptors on MPH-mediated
behavioral alterations has been reported in studies where adminis-
tration of caffeine induces cross tolerance and cross desensitization to
MPH (Boeck et al., 2009; Jain and Holtzman, 2005). In addition, our
group has reported that acute administration of MPH increases
adenosine A1 receptors density in the frontal cortex but its blockade
did not blunt MPH-induced anxiolytic effect (Mioranzza et al., 2010).
Apart from these studies, possible modiﬁcations in the adenosinergic
system in the MPH-mediated effects are still incipient.
Considering the misuse of MPH as a cognitive enhancer, the
present study was designed to assess if acute and chronic treatment
MPH and an acute overdosage of MPH in adult mice could promote
beneﬁcial effects on aversive and recognition memory. Besides, the
involvement of adenosine A1 receptors was investigated in the MPH-
mediated behavioral alterations.
2. Methods
2.1. Animals
Male albino CF1mice (3–4 months old) were obtained from Stated
Foundation for Health Science Research (FEPPS, Porto Alegre/RS,
Brazil). All experimental procedures were performed according to the
NIH Guide for Care and Use of Laboratory Animals and to the Brazilian
Society for Neuroscience and Behaviour (SBNeC) recommendations
for animal care. Experimental procedures were approved by the
ethical committee of Federal University of Rio Grande do Sul and all
adequate measures were taken to minimize pain or discomfort. Mice
were housed in standard cages (4 animals per cage) under a reversed
12/12 h–light/dark cycle with free access to food andwater. The lights
are turned on at 7:00 p.m. All behavioral tests were performed
between 8:00 am and 5:00 p.m. Separate groups of mice were used
for each behavioral task.
2.2. Drugs
A single injection of methylphenidate hydrochloride [MPH, 5 or
50 mg/kg, i.p., diluted in saline (0.9 g %, i.p) with a drop of Tween 20]or saline was administered tomice immediately after training sessions
for behavioral analysis. For chronic treatment, MPH (5 mg/kg, i.p) was
administered during 15 consecutive days. MPH 5 mg/kg has been
widely used in behavioral studies in mice at different ages (Guerriero
et al., 2006; McFadyen-Leussis et al., 2004). In order to avoid possible
acute effects of the drug, the last injection was performed 12 h before
mice had been submitted to behavioral tests. The adenosine A1
receptor selective antagonist 8-cyclopentyl-1,3-dipropylxanthine
(DPCPX, 1 mg/kg, i.p) (Tocris, São Paulo, Brazil)was used andprepared
at the day of experiments from a stock solution diluted in DMSO
(10% v/v) plus saline. This dose was chosed based on previous studies
in which no behavioral alterations were observed (El Yacoubi et al.,
2000; Mioranzza et al., 2010; Pires et al., 2009). Control mice received
saline (0.9 g %) with a drop of Tween 20 or saline (0.9 g %). The ﬁnal
solution of DPCPX administered to mice contained DMSO 0.1% diluted
in saline (0.9 g %).
2.3. Inhibitory avoidance task
Methylphenidate hydrochloride (MPH, 5 or 50 mg/kg, i.p) was
administered to mice immediately after training session. For chronic
treatment,MPH (5 mg/kg, i.p)was administered during 15 consecutive
days and the last injection was performed 12 h before mice had been
submitted to training session.
The inhibitory avoidance task was assessed in an apparatus that
consisted of an acrylic box (50×25×25 cm) whose ﬂoor contains
parallel caliber stainless-steel bars (1 mmdiameter) spaced 1 cmapart.
A platform (2 cm high and 4 cm×6 cmwide) was placed in the center
of the box. In the training session,micewere placed on the platformand
the latency to step-down on the ﬂoorwith the four pawswasmeasured
with an automatic device immediately after stepping-down mice
received a 0.5 mA, 2 s foot shock. After theyhad received the foot shock,
micewere immediately placed back in their home cage. The test session
was carried out 90 min after training (short-termmemory) or 24 h after
training (long-term memory). No foot shock was given in the test
session, and step-down latencies (180 s ceiling) were taken as a
measure of retention.
2.4. Object recognition task
DPCPX was administered thirty minutes prior to the training
session. A single injection of methylphenidate hydrochloride (MPH 5
or 50 mg/kg, i.p) was administered to mice immediately after training
sessions. For chronic treatment, MPH (5 mg/kg, i.p) was administered
during 15 consecutive days. In order to avoid possible acute effects of
MPH, the last injection was performed 12 h before mice had been
submitted to training session. The object recognition task was
performed according to previously reported (Costa et al., 2008) and
following the guidelines previously recommended (Bevins and
Besheer, 2006). The apparatus consisted of a painted wood small
chamber with the following dimensions: 25×25 cm; (lenght×width).
Mice had been acclimated in the apparatus during tenminutes twenty-
four hours before training session. The training session consisted of
placing a mouse in the apparatus containing two identical objects, and
allowed it to explore for 10 min. The objects were positioned in two
adjacent corners, 9 cm from the wall. Eachmousewas always placed in
the apparatus facing the wall. The test session was performed 90 min
after training, and twodissimilar objectswere present, the familiar (one
of the objects used in the training session) and a novel one. Both objects
presented similar textures, colors and sizes, but different shapes in the
test session (Duplo Lego toys). The objects and the apparatus were
cleaned with 10% ethanol solution between trials. Exploration was
deﬁned as directing the nose to the object at a distance of nomore than
2 cm and/or touching the object with the nose or forepaws. Sitting or
leaning on the object without focused was not considered as
exploratory behavior. For training session the index was calculated by
Fig. 1. Acute treatment with methylphenidate (MPH) on the performance in the
inhibitory avoidance task. Adultmice receive a single injectionofMPH (5or 50 mg/kg, i.p)
or vehicle immediately after training session. A — Test session performed 90 min after
training (short-termmemory). Results aremedian and interquartile ranges of step-down
latency in seconds (s) from11 to 12mice per group. B— Test session performed 24 h after
training (long-term memory). Results are median and interquartile ranges of step-down
latency in seconds (s) from 11 to 12 mice per group. **Pb0.05; different from latencies
obtained in the test session for saline-treated mice (Kruskal–Wallis followed by Dunn's
post hoc test). *Pb0.05; differences between latencies from training and test sessions
within group (Wilcoxon test).
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in the test session and the total time of exploration. Considering that
during training session both objects are novel, the time spent on both
objects should be similar and the recognition index should be around
0.5. For calculating training index, the time spent on the object that
will be the familiar in the test session was used. Recognition index
for the novel object eachmouse was expressed by TN/(TN+TF) ratio
[TF = time spent exploring familiar object; TN = time spent
exploring the novel object]. Two experienced observers blind to the
drug treatment performed the behavioral analysis.
2.5. SDS-PAGE (sodium dodecyl sulfate-polyacrilamide) immunoblotting
Twenty-four hours after behavioral tests, mice were sacriﬁced by
cervical displacement; the hippocampus and pre-frontal cortex were
dissected out and immediately homogenized in 5% SDS with a
protease inhibitor cocktail (Sigma, São Paulo/Brazil) and frozen at
−70 °C. After defrost, the protein content was determined by
Bicinchoninic acid assay using bovine serum albumin (BSA) as
standard (Pierce, São Paulo/Brazil). Samples extracts were diluted to
a ﬁnal protein concentration of 2 μg/μL in SDS-PAGE buffer. Forty
micrograms of the samples and prestained molecular weight
standards (Bio-Rad, São Paulo/Brazil) were separated by SDS-PAGE
(12% with 4% concentrating gel). After electro-transfer, the mem-
branes were blocked with Tris-buffered saline 0.1% Tween-20 (TBS-T)
containing 3% BSA for 1 h. The membranes were then incubated for
24 h at 4 °C with rabbit anti-adenosine A1 receptor antibody (1:1000;
Afﬁnity Bioreagents, U.S.A). After primary antibodies incubation,
membraneswerewashed and incubated with horseradish-peroxidase
conjugated secondary antibodies for 2 h at room temperature and
developed with chemiluminescence ECL kit (Amersham, São Paulo/
Brazil). The autoradiographic ﬁlms were scanned and densitometric
analyses were performed using public domain NIH Image Program
(developed at the U.S. National Institutes of Health and available on
the internet at http://rsb.info.nih.gov/nih-image/). The control of
protein loading was carried out with Ponceau S. stain. Membranes
with Ponceau S. were scanned at 37 kDa and the values used to obtain
adenosine A1 receptor density/Ponceau S. density ratio. No differences
were found in the amount of protein loaded (data not shown).
2.6. Statistical analysis
For the inhibitory avoidance task some animals reached the ceiling
of 180 s and the data distribution did not follow Gaussian curve. Thus,
the step-down latencies were expressed as medians (interquartile
ranges) and non-parametric analysis was performed by using
Wilcoxon test for differences between training and test latencies of
the same group. Kruskal–Wallis followed by Dunn's Multiple
comparison test was used to compare treatments. For object
recognition test, two-way ANOVA (treatment×trials) as repeated
measures (as independent variables) was performed. For immuno-
blotting, data were analyzed by using Student's t-test between groups.
Graphpad Prism 5 and SPSS were the softwares used and signiﬁcant
differences were considered when Pb0.05.
3. Results
3.1. Acute administration of methylphenidate in the inhibitory avoidance
task performance
The administration of MPH 5 mg/kg immediately after training did
not modify the latencies between training and test compared to
saline-treated mice when test session was performed 90 min (Fig. 1A)
as well as 24 h after training (Fig. 1B). However, latencies were
statistically different between mice treated with an overdosage ofMPH 50 mg/kg and saline only for test session performed 90 min
(Fig. 1A) but not for 24 h after training (Fig. 1B).
3.2. Chronic administration of methylphenidate in the inhibitory
avoidance task performance
Mice submitted to the chronic treatment with MPH 5 mg/kg were
also evaluated in the inhibitory avoidance task. The latencies of
training and test session between saline and MPH-treated mice were
not statistically signiﬁcant for test session performed 90 min after
training as well as for 24 h (data not shown).
3.3. Acute treatment of methylphenidate in the object recognition task
The inﬂuence of chronic and acute treatment with MPH 5 mg/kg
and an acute overdosage of 50 mg/kg was investigated in the novel
object recognition task that consists on a non-aversive task. Two-way
ANOVA analysis for the total exploration time in both objects for acute
administration of MPH 5 mg/kg revealed a signiﬁcant effect of trials
(as repeated measures) [F (1,41)=46.88; Pb0.001] but no signiﬁcant
interaction between trials and treatment (Fig. 2A). As a normal
behavior, mice spent less time on the familiar object in the test session
when comparing to training. Two-way ANOVA treatment×trials
(as repeated measures) revealed only a signiﬁcant main effect of
trials [F (1,41)=77.59; Pb0.001] (Fig. 2B). For the object recognition
index, two-way ANOVA revealed a signiﬁcant main effect of trials and
signiﬁcant interaction [F (1,41)=4.24; P=0.0405] (Fig. 2C). As
observed, acute administration of MPH 5 mg/kg caused an increase
in the object recognition index.
The acute administration of MPH 50 mg/kg did not affect the total
exploration time in both objects since two-way ANOVA analysis
revealed only signiﬁcant effect of trials [F (1,20)=88.87; = Pb0.001]
Fig. 2. Acute treatment with methylphenidate (MPH) on the performance in the object
recognition task. Adult mice received a single injection of MPH (5 mg/kg, i.p) or vehicle
immediately after training session. A – Total time spent in both objects during training
and test session performed 90 min after training. Results are mean±S.E.M from 21
mice per group. B— Time spent in the familiar object in both sessions (training and test
session) Results are mean±S.E.M from 21 mice per group. C — Recognition index
obtained from training and test session. Results are mean±S.E.M from 21 per group
mice. *Pb0.05; differences within group (training and test session) (two-way ANOVA).
**Pb0.05; differences within groups and from saline-treated mice recognition index
(two-way ANOVA).
Fig. 3. Acute treatment with methylphenidate (MPH) on the performance in the object
recognition task. Adult mice received a single injection of MPH (50 mg/kg, i.p) or
vehicle immediately after training session. A — Total time spent in both objects during
training and test session performed 90 min after training. Results are mean±S.E.M
from 10 to 12 mice per group. B — Time spent in the familiar object in both sessions
(training and test session) Results are mean±S.E.M from 10 to 12 mice per group.
C — Recognition index obtained from training and test session. Results are mean±S.E.
M from 10 to 12 mice per group. *Pb0.05; different from MPH-treated mice and
training session within group (two-way ANOVA).
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3.35; Pb0.09]. The same result was observed for the time spent in the
familiar object, since two-way ANOVA revealed only signiﬁcant effect
of trials [F (1,20)=97.88; = Pb0.001] (Fig. 3B). For the object
recognition index, two-way ANOVA revealed a signiﬁcant interaction
[F (1,20)=7.07; P=0.0151] but no signiﬁcant effect of trials (Fig. 3C).
Thus, the overdosage of MPH 50 mg/kg decreased object recognition
index in the test session.3.4. Chronic treatment with methylphenidate in the object
recognition task
The chronic treatment with MPH 5 mg/kg was also evaluated on
recognition memory. Analysis of time spent on the familiar object
revealed a signiﬁcant effect of trials [F (1,16)=69.95; = Pb0.001]
(Fig. 4A). Likewise, two-way ANOVA analysis for recognition index
also revealed only a signiﬁcant effect of trials [F (1,16)=5.84; =
P=0.0279] (Fig. 4B).3.5. The effect of blockade of adenosine A1 receptors on MPH-induced
recognition memory impairment
The involvement of adenosine A1 receptors in the recognition
memory impairment by MPH 50 mg/kg was investigated with the
selective adenosine A1 receptor antagonist DPCPX (1 mg/kg, i.p)
administered 30 min before training session. MPH (50 mg/kg, i.p) was
administered immediately after training. According to previous data,
MPH 50 mg/kg did not modify the time spent in the familiar object
and administration of DPCPX alone did not cause any effect (data not
shown). Two-way ANOVA analysis of the recognition index revealed a
signiﬁcant effect of trials [F (1,48)=33.42; Pb0.001] and interaction
[F (1,48)=3.47; P=0.0206]. Consequently, pre administration of
DPCPX prevented the decrease on the recognition index caused by
post training administration of MPH 50 mg/kg (Fig. 5).
3.6. Chronic administration of methylphenidate on adenosine A1
receptors immunocontent
Immunoblotting analysis was carried out in the frontal cortex and
hippocampus homogenates from mice treated chronically with saline
Fig. 4. Chronic treatment with methylphenidate (MPH) on the performance in the
object recognition task. Adult mice received a single injection of MPH 5 mg/kg or
vehicle during 15 consecutive days. The last dose of MPH was administered 12 h prior
to training session. A — Time spent in the familiar object in both sessions (training and
test session). Results are mean±S.E.M from 9 mice per group. B — Recognition index
obtained for training and test session. Results are mean±S.E.M from 9 mice per group.
*Pb0.05; different from training session within group (two-way ANOVA).
Fig. 6. Immunoblotting analysis of the adenosine A1 receptor density in the frontal
cortex and hippocampus from adult mice. Mice chronically treated either with vehicle
or methylphenidate (MPH, 5 mg/kg, i.p. 15 days). Data are mean±S.E.M of density unit
lines obtained for adenosine A1 receptor/Ponceau staining (n=5 mice/group for
hippocampus), (n=6 mice/group for frontal cortex). At the top of ﬁgure are
representative bands for adenosine A1 receptor at 37 kDa (saline-treated mice;
5-methylphenidate-treated mice). *Pb0.05, means signiﬁcant difference between
MPH- and saline-treated mice (Student's t-test).
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5 mg/kg decreased the density of adenosine A1 receptor only in the
hippocampus (15%) compared to saline-treated mice (Fig. 6)
(t=2.855; P=0.03).4. Discussion
In this study, the acute and chronic administration as well as an
overdosage of methylphenidate caused behavioral alterations in adult
animals. Here, acute and chronic administration of MPH 5 mg/kg and
an acute overdosage to model misuse presented distinct effects
according to the task used for evaluating memory. Besides, the role of
adenosine A1 receptors was involved in the effects of MPH on
recognition memory.Fig. 5. Blockade of adenosine A1 receptors prevents MPH-induced impairment on
memory recognition. DPCPX (1 mg/kg, i.p) was administered 30 min before training
session. MPH (50 mg/kg, i.p) was administered immediately after training. Recognition
index obtained from training and test session performed 90 min later. Results are
mean±S.E.M from 12 to 15 mice per group. *Pb0.05; different from training session
within group (two-way ANOVA). **Pb0.05; different from recognition index in the test
session obtained for MPH-treated mice (two-way ANOVA).Recognition memory was assessed in the novel object recognition
task, which deals with the natural ability of animals to explore
novelties. In this study, chronic administration of methylphenidate in
a dose used in behavioral studies with juvenile mice did not cause any
effect on both types of memory in adult mice whereas acute
administration improved recognition memory. One explanation for
this improvement could be attributed to both dopamine and
norepinephrine-enhancing properties of the drug. Stimulant drugs,
such as methylphenidate, raise extracellular dopamine levels sup-
posedly by blockade of the dopamine transporter. This mechanism
prevents reuptake of dopamine into the neuron, which results in
higher extracellular dopamine levels (Madras et al., 2005; Volz et al.,
2005). Additionally, acute administration of methylphenidate redis-
tributes vesicular monoamine transporter 2 (VMAT2) protein from
membrane associated vesicles fraction to cytoplasmic vesicles, which
results in an increase in dopamine content in both fractions
(Fleckenstein et al., 2009; Volz et al., 2008). Recent experimental
evidence have demonstrated that dopamine is essential for memory
consolidation in a variety of behavioral tasks, such as the hidden
version of the water maze, the object–place association, and the one-
trial inhibitory avoidance tasks (Dalley et al., 2005; Ferretti et al.,
2005; Setlow and McGaugh, 2000). Besides, dopamine signaling is
crucial for memory persistence as evidenced in the one-trial
inhibitory avoidance task (Rossato et al., 2009).
Interestingly, the acute overdosage impaired both types of
memory but the magnitude of memory impairment was dependent
on the type of memory assessed, since recognition memory was fully
impaired, while in the inhibitory avoidance taskmemorywas partially
impaired. In fact, in the inhibitory avoidance task mice treated with
the overdosage of methylphenidate presented differences between
training and test latencies indicating that they recalled the aversive
stimuli (foot shock), but not at the same level of saline-treated mice.
Therefore, MPH disrupts recognition memory and worsens the
performance in the inhibitory avoidance task when short-term
memory was assessed. Aversive and recognition memories share the
functioning of some brain areas such as the hippocampus, ventral
tegmental area, striatum and pre-frontal cortex. Differently from
object recognition task, the amygdala is highly involved in memories
with emotional component such as those assessed in the inhibitory
avoidance task. The differences found for the effects of methylphe-
nidate according to the type of memory assessed could be due to the
fact that this drug administered intraperitoneally increases the
extracellular dopamine levels in the striatum, nucleus accumbens
and pre-frontal cortex, with no clear evidences of increase in the
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administration of methylphenidate in the lateral amygdala enhanced
cue-reward learning through dopamine D1 receptor-dependent
mechanisms and suppressed task-irrelevant behavior through D2
receptor-dependent mechanisms. These ﬁndings suggest distinct
roles for dopamine receptor subtypes in mediating methylpheni-
date-induced enhancements of neural transmission and learning
performance (Tye et al., 2010). It is likely that overactivation of
dopamine and norepinephrine may contribute to the disruption of
learning and memory as well (for review see Arnsten, 2001).
The long-term memory was preserved by the overdosage of MPH
probably due to the fast clearance of this drug, since pharmacokinetic
analysis studies have shown that the half-life of MPH in rodents after
intraperitoneal administration is estimated to be around 1 h (Thai
et al., 1999). In fact, when long-term memory was assessed mice had
received the injection at least 36 h prior to test session.
Chronic administration of MPH 5 mg/kg in adult mice did not
cause any effect on both types of memory. Conﬂicting results with
chronic administration of MPH in different dosing regimen and age
have been reported. For example, the administration of similar regular
dose in previous studies has shown to impair recognition memory,
but the age (periadolescent rats) at the beginning of treatment differs
from our study (Heyser et al., 2004; LeBlanc-Duchin and Taukulis,
2007). However, adult rats treated with MPH 5 and 10 mg/kg showed
impairment on recognition memory but this effect was evident only
14 days later (LeBlanc-Duchin and Taukulis, 2009). In a recent study,
rats presented lower performance in the Water maze test after they
had received MPH (2 mg/kg) from the 15th to the 45th day of age
(Scherer et al., 2010). However, male and female rats treated with
3 mg/kg of MPH from the 22nd to the 39th day of age presented an
improvement on the radial armmaze performance after seven days of
treatment (Zhu et al., 2007). The schedule of administration,
differences between animal species (rats versus mice), age at the
beginning of treatments and strainsmay take part of the discrepancies
found between behavioral ﬁndings. Prominently, animals treated
with MPH presented distinct behavior depending on the circadian
cycle. Similar to our ﬁndings, in the one-trial inhibitory avoidance task
chronic treatment of adult rats during 28 days with MPH (2 mg/kg)
did not cause any effect, but in a multiple trial protocol long-term
memory was impaired when animals were tested at night (Gomes
et al., 2010). Interestingly, in the same study the long-termmemory in
young rats was impaired in the one-trial as well as in themultiple trial
of the inhibitory avoidance task. As ontogenetic differences are
considered one of the main factors responsible for distinct psycho-
pharmacological sensitivity in a variety of species, adolescent rodents
seem to be more sensitive than their adult counterparts to effects
caused by psychostimulants (for review see Spear, 2000).
Alterations in the locomotor activity of mice could interfere in the
performance of the object recognition task, but previous results from
our group revealed that the same dose and schedule of administration
did not alter locomotor activity (Mioranzza et al., 2010). However, a
decrease on novelty seeking or anhedonia caused by an overdosage of
methylphenidate could not be discarded as well as the possibility that
methylphenidate affected motivation, attention, sensorimotor func-
tion, or memory retrieval. Indeed, previous study showed that adult
rats exposed to repeated doses of methylphenidate during their
juvenile were less responsive with respect to motor activation
exhibited by animals when ﬁrst exposed to a novel environment
(Bolaños et al., 2003).
In our previous study, anxiolytic-like effect caused byMPHwas not
blunted by the blockade of adenosine A1 receptors and there was an
up-regulation in the frontal cortex of this receptor by an overdosage of
methylphenidate (Mioranzza et al., 2010). Thus, the up-regulation of
this receptor could be involved in the impairment of recognition
memory observed in this study. Although chronic administration of
MPH was devoid of effect on memory, the immunocontent ofadenosine A1 receptors was decreased in the hippocampus. Overall,
it remains to be determined if acute treatment with MPH could
increase brain adenosine levels and a continuous administration could
trigger the desensitization of adenosine A1 receptors. It is interesting
to note that caffeine, another well-known psychostimulant and a non-
selective adenosine antagonist, also up-regulates adenosine A1
receptors (Svenningsson et al., 1999).
The stimulation of adenosine receptors counteracts the behavioral
effects of dopamine receptor stimulation (Cao et al., 2007; Ferré et al.,
1997). Likewise, adenosine receptor agonists counteract whereas
adenosine receptor antagonists potentiate pharmacological effects of
psychostimulants like cocaine and amphetamines (Poleszak and
Malec, 2003; Popoli et al., 1994; Rimondini et al., 1998). Particularly,
behavioral alterations caused by other psychostimulants acting on
dopaminergic systemwere related to adenosine A1 receptors (Kuzmin
et al., 1999; Poleszak and Malec, 2003). Our results are in agreement
with recent report where DPCPX did not promote any effect on
recognition memory, but its administration was effective in amelio-
rating the impairment of novel object recognition in spontaneously
hypertensive rats (SHR), used as a model of ADHD (Pires et al., 2009).
In human adults with and without ADHD, there are only few
studies that have examined the effects of methylphenidate on
cognitive functions. In adult ADHD some studies found methylphe-
nidate to improve working memory (Kurscheidt et al., 2008; Mehta
et al., 2000; Turner et al., 2005). In healthy subjects, methylphenidate
enhanced performance in a test of spatial working memory and
planning whereas impaired attention and ﬂuency tests (Elliott et al.,
1997). In our study, improvement on recognition memory was
observed with a single dose of methylphenidate acutely administered
while chronic administration did not show any effect. Therefore, our
ﬁndings suggest that chronic use of MPH as a cognitive enhancer did
not offer evident advantages for healthy animals.
5. Conclusion
As a cognitive enhancer, our data showed that methylphenidate
acutely administered in a single dose promoted improvement on
recognition memory. However, the overdosage caused disturbances
in aversive as well as non-aversive memories at least whenmice were
under inﬂuence of this drug, suggesting that misuse of MPH may
impair important cognitive functions. The chronic administration did
not promote neither detrimental nor beneﬁcial effects on memory.
Importantly, methylphenidate-induced impairment on recognition
memory involved adenosine A1 receptors suggesting that this
receptor plays a role in the mnemonic deﬁcits caused by MPH. Since
adenosine is a neuromodulator that controls the dopaminergic
neurotransmission, which is one of the main pharmacological targets
of MPH, it is important to detail the participation of adenosinergic
system in the ADHD and methylphenidate-mediated actions in the
CNS.
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